Clinical Trial Update: A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) [Phase 3]

View source ↗

Summary

Phase 3 study (EMBARQ - ColdU and SD) evaluating barzolvolimab versus placebo for cold-induced urticaria and symptomatic dermographism in adults inadequately co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Urticaria
• Inducible Urticaria
• Symptomatic Dermographism

Drugs mentioned

• Barzolvolimab (barzolvolimab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Status: RECRUITING